COVID-19 therapeutics II: Inhaled antimiR against inflammatory lung damage caused by COVID-19 (CoVmiR) - clinical trial
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 16LW0153
Grant search
Key facts
Disease
COVID-19Start & end year
20212024Known Financial Commitments (USD)
$3,576,252.07Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
LungenClinic Grosshansdorf GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified